Aurinia Pharmaceuticals Inc (AUPH)vsVertex Pharmaceuticals Inc (VRTX)
AUPH
Aurinia Pharmaceuticals Inc
$17.55
-3.24%
HEALTHCARE · Cap: $2.26B
VRTX
Vertex Pharmaceuticals Inc
$491.34
+2.32%
HEALTHCARE · Cap: $124.70B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 3996% more annual revenue ($12.22B vs $298.30M). AUPH leads profitability with a 100.0% profit margin vs 35.5%. AUPH trades at a lower P/E of 8.1x. AUPH earns a higher WallStSmart Score of 69/100 (B-).
AUPH
Strong Buy69
out of 100
Grade: B-
VRTX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AUPH.
Margin of Safety
+48.3%
Fair Value
$949.55
Current Price
$491.34
$458.21 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 53 in profit
Keeps 100 of every $100 in revenue as profit
Strong operational efficiency at 53.3%
Earnings expanding 56.3% YoY
Conservative balance sheet, low leverage
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Earnings expanding 61.4% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
No major concerns identified
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AUPH
The strongest argument for AUPH centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 100.0% and operating margin at 53.3%. Revenue growth of 24.4% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.
Bear Case : AUPH
No major red flags identified for AUPH, but monitor valuation.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
AUPH profiles as a growth stock while VRTX is a mature play — different risk/reward profiles.
AUPH carries more volatility with a beta of 1.43 — expect wider price swings.
AUPH is growing revenue faster at 24.4% — sustainability is the question.
VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
AUPH scores higher overall (69/100 vs 68/100), backed by strong 100.0% margins and 24.4% revenue growth. VRTX offers better value entry with a 48.3% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aurinia Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China. The company is headquartered in Victoria, Canada.
Visit Website →Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?